Novo Nordisk shares slide as major shareholder condemns corporate governance

The public rebuke intensifies scrutiny over board oversight at the pharma giant, adding to pressure from recent weight-loss drug competition concerns.

By Handelsavisen Newsroom · Automated 2026-06-29 08:08 UTC · 1 min read

Novo Nordisk shares fell sharply in early Monday trading in Copenhagen after a major shareholder publicly condemned the company's corporate governance practices.

The investor described the oversight as "extremely poor," marking a significant escalation in tensions between the board and key stakeholders.

1% at the open, but the weight-loss drug maker's decline dragged on broader sentiment.

The C25 index edged up 0.1% at the open, but the weight-loss drug maker's decline dragged on broader sentiment.

The sharp sell-off reflects growing investor anxiety regarding the company's strategic direction and internal controls, rather than just product-specific risks.

This development follows a period of intense market focus on Novo Nordisk's dominance in the obesity treatment sector.

While the company has maintained strong revenue growth, questions about long-term sustainability and board effectiveness have begun to surface among institutional investors.